KalVista Reports Fiscal Third Quarter Results

KalVista Pharmaceuticals, Inc. reports operational and financial results for the fiscal third quarter ended 31 January 2018.

“We are pleased to have the second candidate from our oral HAE portfolio in a Phase 1 trial as we continue to pursue a best-in-class therapy,” said Andrew Crockett, CEO of KalVista.

KalVista has announced the initiation of a Phase 1 trial for KVD900, the second clinical candidate in the HAE portfolio. KalVista also intends to bring at least one additional HAE drug candidate to the clinic before the end of 2018.
(Source: KalVista)

2018-03-16T14:51:36+00:00